ED
BCEL

Exane Derivatives’s Atreca, Inc. Class A Common Stock BCEL Stock Holding History

Exane Derivatives’s Portfolio BCEL Stock Details BCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-8,068
Closed -$130K – 970
2020
Q4 		$130K Hold
8,068
– – 0.04% 355
2020
Q3 		$113K Buy
8,068
+3,798
+89% +$56.6K 0.03% 289
2020
Q2 		$90.9K Hold
4,270
– – 0.02% 309
2020
Q1 		$70.7K Buy
+4,270
New +$77.4K 0.02% 325

Other funds holding BCEL

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

Exane Derivatives's BCEL Position: Q1 2021 in Review

Exane Derivatives sold out of Atreca, Inc. Class A Common Stock (BCEL) in Q1 2021, closing a stake of 8,068 shares — an estimated $130K sold.

Exane Derivatives first reported a position in BCEL in Q1 2020 and held it in 4 quarters. The position peaked at $130K in Q4 2020. 105 funds tracked by Wall St. Rank hold BCEL as of Q1 2021.

  • Exane Derivatives reported no remaining Atreca, Inc. Class A Common Stock position as of Q1 2021 after selling out during the quarter.
  • Exane Derivatives sold 8,068 Atreca, Inc. Class A Common Stock shares in Q1 2021, an estimated $130K.
  • Exane Derivatives first reported a position in Atreca, Inc. Class A Common Stock in Q1 2020 and held it in 4 quarters.
  • Exane Derivatives's Atreca, Inc. Class A Common Stock position peaked at $130K in Q4 2020.
  • 105 funds tracked by Wall St. Rank held Atreca, Inc. Class A Common Stock as of Q1 2021.

Based on Exane Derivatives's 13F filing for Q1 2021, filed 30 Apr 2021.